Bank Julius Baer & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,121
| Closed | -$169K | – | 614 |
|
|
2025
Q1 | $169K | Buy |
+2,121
| New | +$169K | ﹤0.01% | 437 |
|
|
2024
Q2 | – | Sell |
-5,690
| Closed | -$497K | – | 496 |
|
|
2024
Q1 | $497K | Sell |
5,690
-19,890
| -78% | -$1.74M | ﹤0.01% | 317 |
|
|
2023
Q4 | $2.35M | Buy |
25,580
+11,405
| +80% | +$1.05M | 0.01% | 234 |
|
|
2023
Q3 | $1.25M | Buy |
14,175
+9,176
| +184% | +$812K | 0.01% | 243 |
|
|
2023
Q2 | $433K | Sell |
4,999
-2,224
| -31% | -$193K | ﹤0.01% | 349 |
|
|
2023
Q1 | $702K | Sell |
7,223
-2,415
| -25% | -$235K | ﹤0.01% | 310 |
|
|
2022
Q4 | $997K | Sell |
9,638
-2,247
| -19% | -$232K | 0.01% | 267 |
|
|
2022
Q3 | $1.01M | Buy |
11,885
+4,807
| +68% | +$407K | 0.01% | 253 |
|
|
2022
Q2 | $587K | Sell |
7,078
-515
| -7% | -$42.7K | ﹤0.01% | 330 |
|
|
2022
Q1 | $585K | Buy |
7,593
+2,180
| +40% | +$168K | ﹤0.01% | 333 |
|
|
2021
Q4 | $478K | Sell |
5,413
-2,137
| -28% | -$189K | ﹤0.01% | 426 |
|
|
2021
Q3 | $584K | Sell |
7,550
-1,654
| -18% | -$128K | ﹤0.01% | 409 |
|
|
2021
Q2 | $768K | Buy |
9,204
+1,946
| +27% | +$162K | ﹤0.01% | 384 |
|
|
2021
Q1 | $548K | Sell |
7,258
-6,791
| -48% | -$513K | ﹤0.01% | 430 |
|
|
2020
Q4 | $1.23M | Buy |
14,049
+6,748
| +92% | +$592K | 0.01% | 317 |
|
|
2020
Q3 | $55K | Buy |
7,301
+591
| +9% | +$4.45K | ﹤0.01% | 596 |
|
|
2020
Q2 | $828K | Buy |
6,710
+2,219
| +49% | +$274K | 0.01% | 298 |
|
|
2020
Q1 | $379K | Buy |
+4,491
| New | +$379K | 0.01% | 343 |
|